Magnetic marker to judge pathological response to checkpoint therapy in melanoma

Bookmark and Share
Published: 20 Oct 2018
Views: 1700
Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Alexander van Akkooi speaks with ecancer at ESMO 2018 in Munich about a pilot study employing an inserted magnetic marker to help guide lymph node imaging for patients with advanced melanoma who have been treated with nivolumab and ipilimumab.

He highlights the current surgical options which can leave patients with chronic lymphedema, and iodine seeds which expose patients to ongoing radiation.

By comparison, the magnetic marker is effective, well tolerated, and Dr van Akkooi outlines follow-up studies to expand its use.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

  • Categories: